NEUMORA THERAPEUTICS, INC. (NMRA) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $4.15M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $4.15M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $4.15M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 80.73M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 4.15M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $340.00K |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.15M | (m) | (m) | (m) | $80.73M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $5.06M | (m) | (m) | (m) | $83.20M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $3.38M | (m) | (m) | (m) | $87.18M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $549.00K | (m) | (m) | (m) | $45.67M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $644.00K | (m) | (m) | (m) | $40.95M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.05M | (m) | (m) | (m) | $28.38M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $3.31M | (m) | (m) | (m) | $29.91M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $6.11M | (m) | (m) | (m) | $31.80M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.08M | (m) | (m) | (m) | $23.21M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $1.49M | (m) | (m) | (m) | $25.67M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $337.00K | (m) | (m) | (m) | $27.12M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.23M | (m) | (m) | (m) | $32.06M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $7.15M | (m) | (m) | (m) | $29.40M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |